[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Qing Yuan\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":95},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,44,72],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100649837","integrated-prevention-treatment-and-rehabilitation-for-toileting-related-falls-100649837",false,"NCT07738354","Integrated Prevention, Treatment, and Rehabilitation for Toileting-Related Falls","Construction, Validation, and Demonstration of a Comprehensive Prevention, Treatment, and Rehabilitation System for Toileting-Related Falls in Older Adults and People With Disabilities","Inclusion Criteria:\n\n* Age 18 years or older, with no upper age limit.\n* Presence of physical disability, functional limitation, loss of independence, or a need for assistance with daily activities.\n* Presence of at least one risk factor for toileting-related falls, including but not limited to urinary frequency, urinary urgency, nocturia, urinary incontinence, voiding difficulty, overactive bladder, underactive bladder, impaired gait or balance, reduced muscle strength, fear of falling, cognitive or emotional problems, a history of falls, unsafe nighttime toileting, or environmental hazards associated with toileting.\n* Able and willing to participate in the study assessments and follow-up procedures, with assistance from a caregiver when necessary.\n* Written informed consent provided by the participant or, when applicable, by a legally authorized representative.\n\nExclusion Criteria:\n\n* Acute infection or other acute medical condition requiring immediate treatment that would prevent participation in study assessments or interventions.\n* Severe or unstable medical condition that, in the investigator's judgment, would make participation unsafe or interfere with study procedures or follow-up.\n* Severe disturbance of consciousness or other condition that prevents completion of the required assessments and study procedures, even with appropriate assistance.\n* Inability to participate in the planned follow-up or provide sufficient study-related information.\n* Any other condition that, in the investigator's judgment, makes the individual unsuitable for participation in the study.","ALL","18 Years",{"count":19,"type":20},300,"ESTIMATED","INTERVENTIONAL",[23],"NA","Toileting-related falls may result from a combination of urinary symptoms, impaired gait and balance, reduced muscle strength, cognitive or emotional problems, and unsafe environmental conditions. Older adults and people with disabilities may be especially vulnerable because they frequently require assistance or must move quickly, particularly during nighttime toileting.\n\nThis multicenter prospective study will evaluate a comprehensive prevention, treatment, and rehabilitation program for older adults and people with disabilities who are at risk of toileting-related falls. Participants will receive a standardized multidimensional assessment covering urinary function, gait and balance, physical function, psychological and cognitive factors, activities of daily living, previous falls, and environmental risks.\n\nBased on the risks identified, each participant will receive an individualized combination of interventions. These may include urinary symptom management, gait and balance rehabilitation, strength and mobility training, psychological or cognitive support, caregiver education, and modification of the toileting environment. Participants will be followed and reassessed, and their management plans may be adjusted according to changes in risk and clinical condition.\n\nThe study will evaluate the feasibility, implementation, and safety of this integrated care program, as well as changes in toileting-related falls, nighttime falls, urinary symptoms, mobility and balance, activities of daily living, and fear of falling.",[26,27],"Toileting-Related Falls","Fall Risk",[26,29,30],"Fall Prevention","Older Adults","NOT_YET_RECRUITING","2026-07-27",{"date":34,"type":35},"2026-07-31","ACTUAL",{"date":37,"type":20},"2026-08",{"date":39,"type":20},"2028-12",{"name":41,"class":42},"Qing Yuan","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":51,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":21,"phases":56,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":43},"100637322","a-single-center-single-arm-study-to-evaluate-the-safety-and-efficacy-of-ultra-minimally-invasive-prostate-dilation-in-treating-patients-with-significant-obstructive-symptoms-caused-by-benign-prostatic-hyperplasia-100637322","NCT07583706","A Single-center, Single-arm Study to Evaluate the Safety and Efficacy of Ultra-minimally Invasive Prostate Dilation in Treating Patients With Significant Obstructive Symptoms Caused by Benign Prostatic Hyperplasia","UMPD-BPH","Inclusion Criteria:\n\n* Male subjects aged 40 to 80 years with symptomatic benign prostatic hyperplasia (BPH) and obvious bladder outlet obstruction.\n* Subjects with normal sexual life and a sexual partner, and with intact sexual function.\n* International Prostate Symptom Score (IPSS) ≥ 13.\n* Maximum urinary flow rate (Qmax) between 5 and 10 mL\u002Fs, with a minimum voided volume ≥ 150 mL.\n* Prostate volume measured by transrectal ultrasound (TRUS) \\\u003C 30 mL. Prostate volume is calculated as length × width × height × 0.52.\n* Subjects who, in the investigator's opinion, are able to complete the study protocol.\n\nExclusion Criteria:\n\n* Subjects who are unable or unwilling to sign the informed consent form (ICF) and\u002For comply with all follow-up requirements.\n* Subjects who are unwilling to abstain from sexual activity or use protective sexual behavior within 90 days after treatment.\n* Prostate-specific antigen (PSA) ≥ 10 ng\u002FmL, unless prostate cancer has been excluded by biopsy.\n* Confirmed or suspected prostate or bladder malignancy.\n* Use of antiplatelet drugs, such as clopidogrel or aspirin, within 10 days before surgery, or planned use within 5 days after surgery.\n* Use of medications within 3 months before surgery that, in the investigator's opinion, may affect sexual function.\n* Presence of neurogenic bladder or detrusor underactivity affecting bladder\u002Fsphincter function.\n* Patients with BPH complicated by acute urinary tract infection, acute prostatitis, or bacterial prostatitis.","MALE","40 Years","80 Years",{"count":55,"type":20},5,[23],"This single-center, single-arm, prospective clinical study aims to preliminarily evaluate the safety and effectiveness of ultra-minimally invasive prostatic dilation using a prostate dilation catheter under real-time transrectal ultrasound (TRUS) guidance in male patients with significant bladder outlet obstruction secondary to benign prostatic hyperplasia (BPH).\n\nA total of 5 eligible male subjects aged 40 to 80 years with symptomatic BPH, International Prostate Symptom Score (IPSS) ≥13, maximum urinary flow rate (Qmax) of 5-10 mL\u002Fs, prostate volume \\\u003C30 mL measured by TRUS, and evident bladder outlet obstruction will be enrolled. All subjects will undergo prostatic balloon dilation with the study device under real-time TRUS guidance. Follow-up assessments will be conducted at 1, 3, and 6 months after treatment.\n\nThe primary effectiveness endpoint is the change in IPSS from baseline at 1, 3, and 6 months. The primary safety endpoints include bladder neck contracture, retrograde ejaculation, device-related severe urinary retention persisting for more than 14 days after healing, new-onset stress urinary incontinence, device-related bleeding requiring transfusion, and device-related urethral or prostatic capsular rupture requiring surgical intervention.\n\nSecondary endpoints include responder rates based on different thresholds of IPSS improvement (≥30%, ≥40%, and ≥50%), changes in Qmax, and changes in visual analogue scale (VAS) scores. Exploratory endpoints include changes in postvoid residual urine volume (PVR) and sexual function assessed by the International Index of Erectile Function (IIEF-5) and the Male Sexual Health Questionnaire-Ejaculatory Dysfunction (MSHQ-EjD).\n\nThis exploratory study is intended to provide preliminary clinical evidence supporting the safety and potential clinical benefit of TRUS-guided ultra-minimally invasive prostatic dilation for BPH-related obstruction and to inform future larger-scale clinical studies.",[59],"BPH (Benign Prostatic Hyperplasia)",[61,62],"Benign Prostatic Hyperplasia","LUTS","RECRUITING","2026-05-07",{"date":66,"type":35},"2026-05-13",{"date":68,"type":35},"2026-01-01",{"date":70,"type":20},"2026-09-01",{"name":41,"class":42},{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":51,"minAge":79,"maxAge":53,"enrollmentInfo":80,"targetDuration":4,"studyType":21,"phases":82,"briefSummary":84,"conditions":85,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":4},"100559008","phase-3-tibial-nerve-stimulation-for-post-bph-overactive-bladder-100559008","NCT06558539","Tibial Nerve Stimulation for Post-BPH Overactive Bladder","Study on the Efficacy of Wearable Transcutaneous Tibial Nerve Stimulation for Persistent Overactive Bladder Symptoms Post Benign Prostatic Hyperplasia Surgery","Inclusion Criteria:\n\n* 1\\. Patients with overactive bladder before benign prostatic hyperplasia 2.Overactive bladder still exists 1 month after the operation of benign prostatic hyperplasia; 3.50 ≤ age ≤80 , male 4.72-hour urination diary showed an average of ≥8 urination times every 24 hours at baseline\n\nExclusion Criteria:\n\n\\-","50 Years",{"count":81,"type":20},90,[83],"PHASE3","A single-center, randomized, parallel-controlled design. Approximately 90 cases of persistent overactive bladder symptoms post benign prostatic hyperplasia surgery are expected to be enrolled. The study participants will be randomly assigned to three groups, with 30 participants in each group.",[86],"Persistent Overactive Bladder Symptoms Post Benign Prostatic Hyperplasia Surgery","2024-08-14",{"date":89,"type":35},"2024-08-16",{"date":91,"type":20},"2024-09",{"date":93,"type":20},"2025-02",{"name":41,"class":42},""]